Company Filing History:
Years Active: 2018-2022
Title: Steve Rust: Innovator in Cancer Treatment
Introduction
Steve Rust is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of binding molecules specific for CD73. With a total of 4 patents, Rust's work is paving the way for new therapeutic approaches in oncology.
Latest Patents
Rust's latest patents focus on anti-CD73 binding molecules, which include antibodies and their antigen-binding fragments. These patents provide pharmaceutical formulations that can be used for the diagnosis and treatment of diseases associated with CD73 expression, particularly cancer. The disclosed methods allow for direct therapy using anti-CD73 binding molecules, such as naked antibodies or antibody-drug conjugates. Additionally, his work encompasses adjuvant therapy with other anticancer agents, including immune checkpoint inhibitors, and combination therapies that can be administered in conjunction with chemotherapy.
Career Highlights
Steve Rust is currently associated with Medimmune Limited, where he continues to advance his research in the field of cancer therapeutics. His innovative approach and dedication to improving patient outcomes have established him as a key figure in the industry.
Collaborations
Rust collaborates with notable colleagues, including Carl Hay and Kris Sachsenmeier, to further enhance the impact of his research and innovations.
Conclusion
Steve Rust's contributions to the field of cancer treatment through his patents and collaborations highlight his commitment to advancing medical science. His work on anti-CD73 binding molecules represents a significant step forward in the fight against cancer.